# OnCo record trop2 (target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/targets/trop2/>
  a schema:BioChemEntity ;
  onco:kind "target" ;
  schema:identifier "trop2" ;
  schema:name "TROP2"@en ;
  schema:description "TROP2 is a surface glycoprotein present at high levels on most epithelial cancers (breast, lung, urothelial, gastric, pancreatic) and at low levels on normal tissue. It does not drive the cancer; it is a delivery address, used by the approved ADCs sacituzumab govitecan and datopotamab deruxtecan and by sacituzumab tirumotecan, with a TROP2 PET tracer in development to pick patients."@en ;
  schema:url <https://onco.cc/targets/trop2/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://www.uniprot.org/uniprotkb/P09758/entry> ;
  onco:tag "adc-target", "pet-target" ;
  schema:alternateName "TACSTD2" ;
  onco:targetClass "surface-antigen" ;
  onco:firstDescribed "1989"^^xsd:gYear ;
  schema:sameAs <https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11530>, <https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000184292>, <https://www.uniprot.org/uniprotkb/P09758/entry>, <https://www.ncbi.nlm.nih.gov/gene/4070> ;
  onco:related <https://onco.cc/biomarkers/trop2-expression/> ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/urothelial/> ;
  onco:drugs <https://onco.cc/drugs/ak146d1/>, <https://onco.cc/drugs/bio-106/>, <https://onco.cc/drugs/datopotamab-deruxtecan/>, <https://onco.cc/drugs/eb-nk-301/>, <https://onco.cc/drugs/lcb84/>, <https://onco.cc/drugs/sacituzumab-govitecan/>, <https://onco.cc/drugs/sacituzumab-tirumotecan/> ;
  onco:trials <https://onco.cc/trials/nct07299747/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-bardia-ascent-trop2-biomarker-ann-oncol-2021/> .